Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-537-2_10

Chapter 10: Future Perspectives-Personalized Nanomedicine and Next-Generation Clinical Trials in Breast Cancer

Sahana HD[1], Mutthuraj Dasegowda[2], Kanthesh M Basalingappa[2*], Subhanshi Vishwas[3]

[1]Department of Biochemistry, The oxford Medical College, Hospital, Yadavanahalli, Bengaluru.
[2]Division of Molecular Biology, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.
[3]Applied Science (Department of Chemistry), Invertis University, Bareilly, 243001, UP, India.
Corresponding Author
Dr. Kanthesh M Basalingappa M.Sc., Ph.D., FIAAM
Orcid: https://orcid.org/0000-0002-6970-4546

Abstract

The chapter highlights the role of personalized nanomedicine in overcoming the limitations of conventional breast cancer therapies by integrating nanocarriers (liposomes, dendrimers, polymeric nanoparticles, exosomes) with precision oncology. These systems enable targeted drug delivery, reduced toxicity, and improved therapeutic outcomes using molecular profiling, multi-omics, and tumor microenvironment insights. To translate these advances clinically, next-generation trial designs (adaptive, basket, umbrella trials), supported by AI, machine learning, digital twins, and real-world evidence, are emphasized as more flexible and efficient than traditional methods. The chapter also discusses preclinical models (organoids, xenografts), as well as regulatory and ethical considerations. Future directions involve combining nanomedicine with immunotherapy, gene editing, and wearable devices, requiring multidisciplinary collaboration to ensure safe and effective clinical translation. Personalized nanomedicine, supported by innovative trials, holds strong promise for shaping the future of precision oncology in breast cancer.

Keywords: *Personalized nanomedicine, Breast cancer, Precision oncology, Targeted drug delivery, Nanocarriers, Adaptive clinical trials, Basket trials, Translational nanomedicine, Artificial intelligence in oncology.*

1. Introduction

Breast cancer remains a major health problem worldwide and over two million new cases are recorded every year; hence it is the most prevalent cancer amongst women globally. Breast cancer is one of the main causes of death due to cancer despite prominent screening, diagnostic, and therapeutic approaches that have been created during the last several decades. It is the fact that the greater part of the reason why this burden is so persevering, that breast cancer is highly heterogeneous, both at the histopathological and molecular scales. The emergence of precision oncology presents an unprecedented opportunity to win the combination of personalized nanomedicine, which offers targeted, patient- offers these issues specific therapies with better efficacy and less toxicity. This convergence, together with advances in clinical trial design, will be a turning point in the path to a new era of personalized breast cancer care [Arnold M et. al., 2022].

Breast cancer challenges – it's heterogeneity and conventional therapy

Breast cancer is not viewed as a single disease, but as a collection of various subtypes that differ in biological behaviour, therapeutical response and clinical prognosis. Traditionally, breast cancer was classified based on histological traits, but emerging molecular biology and high throughput technologies have demonstrated the genomic, transcriptomic, and proteomic heterogeneity that underlies this cancer. The intrinsic molecular subtypes, such as luminal A, luminal B, HER2-enriched, and triple-negative/basal-like reflect the wide spectrum of disease biology and serve to inform prognostication and influence treatment decisions. However, there is still substantial inter- and intra-tumoral heterogeneity even in these subtypes, which is founded to be caused by genetic mutations, epigenetic changes, interactions with the tumor microenvironment, and clonal evolution throughout time [Yersal O *et. al., 2014]*.

The heterogeneity is a contributing factor to some of the major challenges in the management of breast cancer. First, it is the basis of the variable response to the standard therapies. As an example, although endocrine therapies tend to be effective in patients with hormone receptor-positive tumors, de novo and acquired resistance is a significant clinical challenge. Likewise, HER2-directed therapies including trastuzumab and pertuzumab have changed the outcomes of the HER2-positive disease, but resistance inevitably emerges in most patients. Triple-negative breast cancer (TNBC), which does not express estrogen receptor (ER), progesterone receptor (PR), and HER2, is especially problematic because of the lack of clearly defined molecular targets and highly aggressive clinical behavior [Carlino F *et. al., 2024]*.

Second, breast cancer is complex thereby causing therapeutic toxicity. Traditional chemotherapy treatment courses, whereas in many cases effective in inducing tumor

cytoreduction, are not selective and often cause systemic side effects. These toxicities do not only reduce quality of life of patients, but may also restrict dose intensity and duration of treatment, which eventually affects treatment outcome *[Anand U et. al., 2022]*. Moreover, the development of minimal residual disease and micrometastases which are frequently resistant to conventional treatment also makes management more difficult and leads to recurrence and progression. Lastly, the heterogeneity of breast cancer makes it difficult in terms of clinical trials modeling and drug development. The conventional randomized controlled trials (RCTs) are based on the idea of treating rather homogeneous populations of patients, which is not tenable in the setting of molecularly heterogeneous tumors. Consequently, several promising treatments are likely to fail in large clinical trials even when they show activity in a particular molecular subgroup *[Tachtsidis A et. al., 2016]*. It has led to demands of redesigning clinical trials to be more reflective of the nature of breast cancer biology.

The emerging role of personalized medicine in oncology

Personalized medicine Personalized medicine, also known as precision oncology when applied to the treatment of cancer, aims to optimize therapeutic interventions to the individual patient, and takes into account genetic, epigenetic, proteomic and metabolic signatures. In breast cancer, molecular diagnostics, including next-generation sequencing (NGS), gene expression profiling, and liquid biopsies have led to a new era of targeted therapy in which drugs are targeted to take advantage of a particular vulnerability in a tumor. As such, the alteration of HER2 amplification produced HER2-targeted agents, whereas BRCA1/2 mutations identification has allowed applying PARP inhibitors to a specific group of patients [Krzyszczyk P *et. al., 2018]*.

With these developments, the reality of personalized medicine in breast cancer has not been fully realized. One of these shortcomings is the delivery of targeted agents to the correct tumor compartments without normal tissues. The heterogeneous vasculature, dense extracellular matrix and immunosuppressive microenvironment that comprise the biological barriers to drug delivery, can limit penetration of therapies and their effectiveness. Further, tumor development within the therapeutic pressure leads to the emergence of resistant clones, which requires flexible and dynamic treatment approaches [Mehta R *et. al.*, 2011]. It is in this light that customized nanomedicine has a lot of promise. With the ability to engineer nanoscale drug delivery vehicles that may be tailored to the tumor features of a patient, one can achieve enhanced accumulation of drugs at the tumor site, enhanced uptake by the cells and the ability to modulate the tumor microenvironment to enhance the effects of therapeutic agents. Combination approaches to overcome resistance and induce lasting responses are further facilitated by the co-delivery capacity of various agents (chemotherapeutics, molecular targeted therapies and immunomodulators) in a single nanocarrier *[Alghamdi MA et. al., 2022]*.

Besides drug delivery, nanotechnology can also be applied in detection in early and imaging and real time monitoring of therapeutic response hence it can be said that it can be more holistic and integrated to personalized cancer care. Another example is that contrast agents composed of nanoparticles can be employed to enhance sensitivity and specificity of imaging modalities or nanosensors can be employed to sense biomarkers of minimal residual disease or early relapse. These technologies are perfectly compatible with the ambitions of precision oncology: to administer the right treatment to the right patient, at the right time [Hristova-Panusheva K *et. al.,* 2024].

Nanotechnology and Precision Oncology

The treatment of breast cancer could be completely transformed by the combination of two complementary paradigms: precision oncology and nanotechnology. Nanotechnology provides designer and tuneable systems, which can be directed to respond to particular biological signals, like pH, enzyme activity or redox potential, to achieve spatiotemporally regulated drug release. Such intelligent delivery systems have the ability to selectively accumulate in tumor tissue by passive (e.g., enhanced permeability and retention [EPR] effect) and active (e.g., ligand-receptor interactions) ways, and thus increase therapeutic indices. Precision oncology gives the blueprint to choose suitable molecular targets, therapy agent and patients group *[Chehelgerdi M et. al., 2023]*. Then, through the combination of molecular profiling data with the design of nanocarriers, one can create indeed personalized nanomedicine formulations. As an example, nanoparticles may be functionalized with antibodies or ligands specifically binding to overexpressed receptors on tumor cells, e.g. HER2, EGFR or folate receptors. Equally, nanocarriers may be filled with small interfering RNA (siRNA), microRNA, or CRISPR-Cas9 complex to silence or edit oncogenic drivers revealed by genomic investigations. Furthermore, co-delivery of medicines that target complementary pathways is made possible by nanotechnology, offering the possibility of synergistic therapy [Sabit H *et al.,* 2025]. For example, co-encapsylation of an immune checkpoint inhibitor with a chemotherapeutic drug into the same nanocarrier can result in anti-tumor immunity with less systemic toxicity. When treating triple-negative breast cancer, where immunotherapy has given hope but immune escape is a common drawback, these strategies are particularly alluring. Therapeutic resistance is another area where precision oncology and nanotechnology meet. By combining pathway inhibitors, altering the tumor microenvironment, or offering medicines capable of reversing epigenetic modifications, personalized nanomedicine can overcome the multifactorial character of resistance [Boone CE *et al.,* 2022]. Additionally, stimuli-responsive nanocarriers can be used to deliver drugs on-demand in response to specific tumor-associated signals, thereby increasing efficacy and reducing off-target effects. The convergence of precision oncology and nanotechnology in clinical development suggests the need for novel trial designs that can accommodate the dynamics and complexity of individualized

nanomedicine. Advanced clinical trials provide flexible and efficient venues for testing various treatments, including adaptive, basket, and umbrella trials. These designs allow for the simultaneous evaluation of many therapy methods, the inclusion of molecularly defined subgroups, and the real-time modification of research parameters based on accumulating data [Ho D *et al.*, 2020]. Notably, the junction of these fields-which include nanotechnology, pharmacology, bioinformatics, clinical medicine, regulatory science, and molecular oncology-requires interdisciplinary collaboration. It also emphasizes how crucial it is to address ethical and legal issues in order to safely, fairly, and socially acceptably realize the advantages of individualized nanomedicine. This link between precision oncology, nanotechnology, and breast cancer heterogeneity is one of the most exciting developments in modern cancer treatment. Future clinical trials and personalized nanomedicine hold promise for more efficient, less harmful, and, yes, customized treatment that is tailored to each patient's needs. In order to reinvent breast cancer treatment for the next generation, the authors of this chapter will discuss the scientific underpinnings, current developments, and future prospects of this ever-evolving discipline as well as how benchside ideas could be turned into bedside remedies [Guo L *et al.*, 2023].

Table 10.1: Breast Cancer Heterogeneity, Conventional Therapy Challenges, and Solutions via Personalized Nanomedicine

Aspect	Breast Cancer Heterogeneity / Conventional Therapy Challenges	Personalized Nanomedicine + Precision Oncology Solutions	References
Tumor Biology	Diverse molecular subtypes (Luminal A/B, HER2+, TNBC); genetic and epigenetic variability; clonal evolution; dynamic tumor microenvironment	Nanocarriers tailored to molecular subtypes; co-delivery of multiple agents; tumor microenvironment-responsive nanomedicine	*[Orrantia-Borunda E et. al., 2022]*
Therapeutic Targets	Lack of universal targets; target heterogeneity within and between tumors; emergence of resistant clones	Ligand-functionalized nanoparticles targeting specific receptors (e.g., HER2, EGFR); RNAi/CRISPR delivery for gene silencing/editing	[Chehelgerdi M *et. al.*, 2023]
Drug Delivery	Non-specific drug distribution; poor penetration into tumor core; systemic toxicity	Enhanced permeability and retention (EPR) effect exploitation; active targeting via functionalized nanocarriers; stimuli-responsive drug release	*[Mi P et. al., 2020]*

Treatment Resistance	De novo or acquired resistance to endocrine, HER2-targeted, and chemotherapeutic agents	Co-delivery of agents targeting complementary pathways; modulation of tumor stroma and immune microenvironment; epigenetic-targeting nanocarriers	*[Lei ZN et. al., 2023]*
Toxicity and Side Effects	Off-target toxicity; dose-limiting adverse effects reducing treatment compliance	Tumor-selective accumulation; reduced systemic exposure; controlled drug release minimizing toxicity	*[Ezike TC et. al. 2023,]*
Clinical Trial Limitations	Traditional RCTs poorly suited for molecular heterogeneity; long timelines; high cost	Adaptive, basket, and umbrella trial designs; real-time stratification of molecular subgroups; integration of AI and digital twins for trial optimization	*[Tarride JE et. al., 2022]*
Monitoring and Imaging	Difficulty in detecting minimal residual disease; late detection of relapse	Nanoparticle-based imaging agents; nanosensors for early biomarker detection; real-time therapy monitoring	*[Swierczewska M et. al., 2012]*

2. The Concept of Personalized Nanomedicine

Definition and Scope of Personalized Nanomedicine

With diagnostic, therapeutic, and monitoring methods tailored to the molecular and physiological peculiarities of a given patient's illness, personalized nanomedicine holds great potential as a particularly potent combination of nanotechnology and precision medicine. It encompasses the concept of the right treatment, the right patient at the right time but with the further refinement of nanotechnology-based tools and platforms that allow controlled and site-specific delivery, multimodal therapy and real time monitoring of the disease progression. Personalized nanomedicine offers potential solution in enhancing clinical outcome in the setting of breast cancer where tumor heterogeneity, clonal evolution, and microenvironmental effects play a role in therapeutic resistance and disease progression *[Liu S et. al., 2012]*.

Nanomedicine is the more broadly used term in describing the use of nanoscale materials, usually between 1 to 100 nanometers, in size, to medical ends such as drug delivery, imaging, and diagnostics. The physicochemical properties (size, charge, surface functionality and degradability) of these nanosystems can be designed to confer them with the ability to interact with biological systems in a very specific manner. Personalized nanomedicine takes this a step further where these nanosystems are

personalized to a particular patient depending on their molecular profile- which is becoming more and more available as multi-omics are becoming more and more widely used *[Yusuf A et al., 2023].*

Personalized nanomedicine in breast cancer has wider horizons beyond drug delivery system, as it relates to early diagnosis of disease, real time imaging of therapeutic efficacy and it has the potentiality to reverse the resistance mechanism. As another example, nanoparticle-based sensors could be used to measure circulating tumor DNA or microRNA as minimal residual disease markers, or multifunctional nanocarriers could be used to integrate therapeutic and diagnostic modality (i.e., theranostics) to direct and monitor treatment efficacy in real time. Such combination of therapy, diagnostics and monitoring into one platform is a game changer in the way breast cancer may be treated in the future along the entire continuum *[Sorrentino Cet al., 2024].*

Role of Multi-Omics in Designing Nanotherapeutics

Personalized nanomedicine is based on the prospect to tailor nanotherapeutic approaches to the molecular basis of a tumor of a particular patient. In creating this profound molecular understanding, multi-omics strategies, such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics, are important. All the layers of omics data are complementary and thus used to guide the development of more efficient, specific, and versatile nanocarrier systems. Genomics entails examination of DNA sequence variations, which include point mutations, insertions/deletions, copy number variations and structural rearrangements. Genomic profiling in breast cancer can define actionable mutations (e.g., PIK3CA, BRCA1/2, TP53) and amplifications (e.g., HER2), which can be molecular targets of both small molecule inhibitors and of antibody-functionalized nanoparticles (Figure 10.1). Incorporation of this genomic information allows nanotherapeutics to be developed to target specific agents (e.g., PI3K inhibitors or PARP inhibitors) to tumor cells which contain these mutations, with minimal impact on normal tissues *[Molla G et. al., 2024].*



Figure 10.1: Role of Multi-Omics in Designing Nanotherapeutics

Transcriptomics gives information about patterns of gene expression that determine the subtypes of breast cancer and reflect activated signaling pathways. As an example, a high mRNA expression of immune evasion genes, angiogenesis, or epithelial-mesenchymal transition (EMT) can be used to co-deliver immunomodulators, anti-angiogenic, or EMT inhibitors in a nanocarrier. Also, Transcriptomic profiling can define RNA-based therapeutic targets, and therefore, siRNA or microRNA mimics can be incorporated in nanocarriers to specific downregulate oncogenic transcripts *[Li Y et. al., 2022]*. Proteomics is the complementary technique to genomics and transcriptomics, since it identifies the functional protein networks by which tumors behave. Because proteins are the effectors of cellular function par excellence, proteomic data assist in the identification of overexpressed surface receptors (e.g., EGFR, folate receptor, integrins) that can be targeted actively to nanoparticles. Such information will be especially useful in the engineering of surface-functionalized nanocarriers ligands, antibodies or aptamers that selectively bind and internalize in tumor cells. Metabolomics provides a dynamical map of the metabolic activity of the tumor and of the tumor microenvironment. In breast cancer, the reprogrammed glucose metabolism (the Warburg effect), lipid metabolism, and redox balance offer chances to develop metabolically responsive nanocarriers. As an illustration, nanocarriers that discharge their cargo in answer to the acidic pH of the tumor or the elevated concentrations of reactive oxygen species (ROS) found in the tumor microenvironment can increase selectivity and therapeutic index *[Zhou Z et. al., 2024]*. Collectively, multi-omics data will allow a systems-level map of the breast cancer

disease biology that will inform the rational design of tumor-specific nanotherapeutics that can adapt to the changing molecular landscape of the disease. Noteworthy, omics-guided design in combination with artificial intelligence and machine learning has a potential to speed up the creation of such intricate nanosystems.

Nanocarrier Platforms for Personalized Therapy

An extensive variety of nanocarrier platforms has been investigated in breast cancer therapy, and each of them has distinct characteristics which can be exploited in personalization (Figure 10.2).

Liposomes

Liposomes refer to spherical vesicles that consist of lipid bi-layers enclosing an aqueous center. They are very versatile since they can entrap hydrophilic as well as hydrophobic agents. PEGylation (surface modification with polyethylene glycol) can increase circulation time, and ligands or antibodies can be attached to achieve active targeting to particular receptors on tumor cells. Some liposome-based therapeutics are doxorubicin-loaded liposomes (Doxil ®), which have shown to be less cardiotoxic than free doxorubicin *[Nsairat Het. Al., 2022]*.

Dendrimers

Dendrimers are well defined, highly branched, tree-like polymers that possess multiple surface functional groups. These surface groups may be prepared to warrant targeted delivery, release control, or co-delivery of several agents. Dendrimers have accurate size and functional control that can achieve pharmacokinetics and biodistribution fine-tuning. These are especially well adapted to complex formulations where multiple functionalities are required e.g. delivery of drugs and genetic material in the same construct *[Choudhary S et. al., 2017]*.

Polymeric Nanoparticles

Polymeric nanoparticles Polymeric nanoparticles are made by using biodegradable polymers, e.g. poly (lactic-co-glycolic acid) (PLGA), and offer sustained and controlled drug release. They can be designed to react to certain stimuli within the tumor microenvironment (e.g., pH, enzymes) and can co-encapsulate multiple agents. They can have their surface functionalized to enable active targeting or stealth capability and thus can be customized to personalize their use *[Alsaab HO et. al., 2022]*.

Metallic Nanoparticles

Metallic Nanoparticles Metallic nanoparticles such as gold nanoparticles and iron oxide nanoparticles have distinct optical and magnetic properties which can be used in therapy

as well as diagnosis. Altogether, nanoparticles can be applied to photothermal therapy, such as gold nanoparticles, where the local heating by near-infrared light destroys the tumor cells. They can be functionalized with targeting ligands or drugs loaded onto their surfaces to allow combined therapy and imaging ("theranostics") *[Baranwal Jet. Al., 2023].*

Exosomes

Natural nanoscale vesicles Exosomes are naturally occurring nanoscale vesicles released by cells, involved in intercellular communication. Their biocompatibility and the natural capability to penetrate the biological barriers make them appealing vehicles to deliver personalized nanomedicine. Exosomes can be manipulated to carry drugs, RNA therapeutics or imaging agents and still maintain low immunogenicity and cellular uptake *[Sen S et. al., 2023].* All of these platforms present unique opportunities in overcoming the issues of breast cancer heterogeneity. Most of the nanocarrier systems are targeted based on molecular and physiological characteristics of the tumor of a particular patient denoted by multi-omics profiling.



Figure 10.2: Overview of nano-carrier platform for Breast Cancer

Tumor Microenvironment-Responsive and Stimuli-Sensitive Nanomedicine

Tumor microenvironment (TME) is the key to breast cancer development, metastasis, and therapeutic resistance. The TME, marked by hypoxia, acidity, high level of ROS, abnormal vasculature, and immunosuppressive cells presents a number of features that

can be exploited to develop smart nanomedicines. pH-sensitive nanocarriers are developed to decide the release of their burden in the acidic condition where the tumor is located (pH 6.5 6.8) or in endosomes/lysosomes (pH 5 6) following cell internalization. These systems are employed to reduce the premature release of the drug in the circulation and to increase tumor specific delivery. Redox-sensitive nanocarriers take advantage of the fact that tumor cells have high rates of intracellular glutathione (GSH) when compared to normal cells. Such carriers include disulfide bonds which are broken in the reducing conditions within the tumor, leading to drug release. Enzyme-sensitive nanoparticles take advantage of the fact that tumor-associated enzymes, including matrix metalloproteinases (MMPs) or cathepsins are overexpressed at the tumor site to cause degradation of the nanoparticle matrix or release of the therapeutic agent at the tumor site (Figure 10.2) *[Feng Y et. al., 2024].* Activation of hypoxia-responsive systems occurs in low oxygen environments such as those found in many solid tumors, allowing the highly selective drug release in hypoxic areas which are commonly resistant to standard therapy. Systems which are externally triggered, either by light (photodynamic or photothermal therapy), ultrasound, or magnetic fields, add further levels of control over drug release, enabling clinicians to adjust therapy in real time. By adding these stimuli-responsive characteristics to the nanocarriers made according to the tumor's molecular profile, personalized nanomedicine can deliver drugs with extreme precision. This reduces the likelihood of side effects and systemic toxicity while also increasing therapeutic benefit. The concept of tailored nanomedicine, which combines the power of nanotechnology with the insights from multi-omics profiling, is an essential step in the treatment of breast cancer. Personalized nanomedicine has the potential to address tumor heterogeneity, address the limitations of conventional therapies, and provide patient-specific solutions by leveraging the advantages of sophisticated nanocarrier platforms and tumor-responsive formulations. As the biology of breast cancer is better understood and technology to create nanocarriers and molecularly profile malignancies advance, tailored nanomedicine will play an even bigger role in precision oncology in the future [Kumari R *et. al.* 2020, Vasudev V. *et. al*., 2024].

3. Nanomedicine Tailored to Breast Cancer Subtypes

One of the most prevalent tumors in the world, breast cancer exhibits a great deal of molecular variability that leads to a variety of clinical outcomes. The significance of a tailored approach to treatment is underscored by the molecular separation of breast cancer into three subgroups: hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC). Standard therapies have limitation in terms of systemic toxicity, drug resistance as well as the failure to target tumor microenvironmental effects. By their exact targeting capabilities, multifunctionality and tunable physicochemical properties, nanomedicine provides new

solutions to these challenges. nanotechnology solutions against each of the major subtypes of breast cancer and examine how nanomedicine can be combined with newer therapies approaches, such as immunotherapy and gene editing. Nanotechnology Solution to Hormone Receptor Positive Breast Cancer, approximately 70 percent of breast cancers are hormone receptor-positive, which means they contain estrogen receptors (ER) and/or progesterone receptors (PR) or both. The standard of care is endocrine therapy (e.g., tamoxifen, aromatase inhibitors). Nonetheless, the clinical challenges are met by resistance, either de novo or acquired. ER-growth factor signaling (e.g., PI3K/AKT/mTOR) cross-talk and mutations or amplifications in co-regulatory proteins are and causes of therapeutic resistance *[Łukasiewicz S et, al., 2021].*

Nanocarrier strategies

Nanomedicine introduces the possibility of overcoming these limitations through:

1. Co-delivery systems: Nanoparticles modified to entrap endocrine agents (such as tamoxifen) and combine them with PI3K/mTOR inhibitors are able to overcome compensatory signaling and postpone the development of resistance.
2. Stimuli-responsive delivery: Nanoparticles made of polymers that deliver payload optimally in acidic and enzymatically-high tumor microenvironments: very specific.
3. Ligand-modified carriers: Carriers modified with ER or folate receptor ligands enhance the tumor specificity and minimise off-target effects because receptor-targeted nanoparticles are more tumour-selective.

As an example, the cyclic/polymeric micelles that co-deliver everolimus and fulvestrant have shown to increase apoptosis in endocrine-resistant breast cancer models. Estrone functionalized liposomes also have been demonstrated to have a better target and uptake in ER + cell lines *[Pal, Rahul, et al., 2025].*

Treatment to HER2-Positive Breast Cancer using Nanomedicine

Breast cancer that is HER2-positive makes up about 15-20 percent of all breast cancers and it is one in which the HER2 protein is over-expressed. Having greatly improved survival outcomes, HER2-targeted treatments (e.g., trastuzumab, pertuzumab, T-DM1) are limited by, among others, primary or acquired resistance and cardiotoxicity.

There are a number of promising methods that nanotechnology presents:

1. HER2-targeted nanoparticles: Nanoparticles with trastuzumab, affibodies or HER2-specific aptamers are functionalized to have specific delivery and receptormediated endocytosis.
2. Multimodal platforms: Nanoparticles consisting of a combination of chemotherapy, photothermal agents or imaging probes increase the precision of therapy.

3. Riding out resistance: Co- administration of HER2- targeting agents with blockers of down stream signaling (e.g., PI3K, AKT) overriding resistance mechanisms.

As an example, co-loaded paclitaxel, PI3K inhibitors coupled to trastuzumab-modified liposomes have shown much stronger tumor suppression than single therapy. HER2 - targeting gold nanoparticles with added chemotherapeutics provide local control beyond just providing chemotherapies because it allows photothermal ablation *[Mercogliano MF et. al., 2023]*.

4. Nano drug delivery systems in the treatment of TNBC: Prospect and Problems

TNBC is a highly aggressive sub-type of breast cancer that lacks the three receptors namely ER, PR, and HER2 express but has limited targeted forms of treatment. TNBC is especially problematic having high tendencies of early metastasis, chemoresistance, and recurrence.

Nanocarriers provide opportunities to address the unique biology of TNBC:

1. Targeting cancerous stem cells: the hyaluronic combination nanoparticles can target CD44-overexpressing cancer stem cells, giving direct exposure of the drugs or gene therapy to the resistant cell population.
2. Modulation of Tumor microenvironment: Microenvironment modulation induced using liposome or polymeric nanoparticles, carrying agents to deplete or reprogram tumor-associated macrophages (TAMs) redirects the microenvironment in this direction, towards an anti-tumor phenotype.
3. Stimuli-responsive release: Ph-, hypoxia-, or enzyme-activatable nanoparticles can enable intra-tumoral release, and can sweep past the stromal barriers of the dense TNBC microenvironment.
4. Defeating MDR: P-gp mediated efflux of drugs can be overcome by co-encapsulation of better chemotherapeutics with the inhibitor of P-gp into nanoparticles.

Among those are polymeric nanoparticles that carry paclitaxel and a P-gp inhibitor tariquidar that demonstrated increased efficacy using MDR TNBC models. On the same note, exosome-mimicking vesicles have been shown as more penetrating and delivering entities in preclinical TNBC *[Pradhan R et. al., 2023]*.

Combination approaches: Immunotherapy + nanomedicine + Gene Editing

New generation remedial methods of therapy design to combine both immunotherapy and gene editing with nanomedicine in a synergistic way.

Nanomedicine + Immunotherapy

Nanocarriers have the ability of targeting immunotherapeutic agents locally to the tumor site so as to minimize systemic toxicity loss:

1. Checkpoint inhibitors: Nanoparticles carrying anti-PD-1/PD-L1 or anti-CTLA-4 antibodies can reach a high level of concentration locally, and immune-related adverse events are less that way.
2. Vaccine nanocarriers: Nanoparticles which entrap tumor antigens along with T cell stimulants facilitated vigorous T cell reactions.
3. Adjuvant co-delivery: the presence of TLR agonists, STING agonists, or cytokines together co-loaded in nanoparticles stimulates the innate immune system and promotes the adaptive immune response.

An illustration of this was that Lipid nanoparticles loaded with PD-L1 siRNA and STING agonists exhibited a synergistic pattern of tumor regression in TNBC mouse models *[Shi Y et. al., 2019]*.

Nanomedicine + Gene Editing

Gene editing methods, including the CRISPR-Cas9 have tremendous promise, but present difficulties in delivery. Nanoparticles can facilitated an effective delivery of CRISPR constituents: 1. High editing efficiency of Cas9 mRNA and gRNA is obtained in tumor cells using LNPs. 2. Target genes: PD-L1 (in an attempt to stimulate the immune system), MDR1 (effectively counter resistance) or oncogenic drivers. 3. Design: Target nanocarriers are bio-degradable with reduced off-target effects and immunity. Example: In vivo surface delivery of Cas9 of nanoparticles against PD-L1 effectively suppressed tumors over time and also increased the sensitivity to checkpoint blockade *[Givens BE et. al. 2018,]*.

Table 10.2. Summary of Nanomedicine Approaches Across Breast Cancer Subtypes *[Gadag S et. al., 2020]*

Breast Cancer Subtype	**Target**	**Nanocarrier Type**	**Therapeutic Strategy**	**Example**
Hormone receptor-positive	ER, PI3K/mTOR	Polymeric NPs, liposomes	Co-delivery of endocrine agents and pathway inhibitors	Letrozole and everolimus in hybrid NPs
HER2-positive	HER2	HER2-functionalized liposomes, gold NPs	Targeted delivery, photothermal and chemo	Trastuzumab-liposome-docetaxel

TNBC	CD44, TAMs	HA-NPs, polymeric NPs	CSC targeting, microenvironment modulation	Paclitaxel and tariquidar in polymeric NPs
TNBC	MDR1	Lipid NPs	Overcome drug efflux	P-gp inhibitor and chemo co-delivery
All	PD-L1, MDR1	Lipid NPs	CRISPR-Cas9 gene editing	Cas9 mRNA and gRNA targeting PD-L1

Table 10.3. Advantages and Challenges of Nanomedicine Tailored to Breast Cancer Subtypes ***[****Shi J et. al., 2017]***

Subtype	Advantages of Nanomedicine	Challenges / Future Directions
HR+	Precise co-delivery, lower systemic toxicity, delay resistance	Need for better models of acquired resistance, scalability
HER2+	Dual targeting (HER2 and pathway inhibitors), theranostics	Addressing heterogeneity of HER2 expression, immune reactivity
TNBC	TME modulation, CSC targeting, MDR bypass	Heterogeneous target expression, potential for off-tumor effects
All	Platform for multi-agent delivery, integration with immuno/gene therapy	Regulatory hurdles, cost, long-term safety data

An example of it is nanomedicine in breast cancer where we are shifting to precision therapy and leaving behind the one-size-fits all aka to our disease taking into consideration the molecular and microenvironment specificities of a certain subtype. Nanoparticles are offered in the form of individualized care to novel hierchons, HER 2 positive, and triple negative breast cancer with the prospects of overcoming resistance, lower toxicity and augmented efficacy. Co-treatment with immunotherapy and gene editing, which can be transformative in the future, justifies proper optimization of delivery mechanisms, safety and economy. Gestation of good translational research will contribute a lot in optimal functions of nanomedicine in personalization of breast cancer treatment *[Wu D et. al., 2017]*.

Preclinical Tests of Personalized Nanomedicine

An effective out-of-lab transformation of personalized nanomedicine into the clinical setting requires strong, predictative, and physiologically relevant preclinical models. Although these conventional cancer cell line cultures in two-dimension (2D) and murine models can be useful, they are incapable of modeling the complexity of human malignancies due to the absence of growth characteristics of human tumors, such as the tumor microenvironment, genetic heterogeneity, and dynamically interacting cells. The emergent field of tailored nanomedicine-disease conditions specific nanocarriers to the specific biology of each particular tumor and requires next-generation preclinical platforms that increasingly reflect patient-specific disease. In this section, major

preclinical platforms transforming the design and testing of personalized nanotherapeutics in breast cancer will be discussed: patient-derived xenograft (PDX) models, organoid cultures and tumor-on-chip devices in 3D, and modeling of nanocarrier design in silico and with the use of artificial intelligence *[Boix-Montesinos P et. al., 2021]*.

Patients Derived Xenograft (PDX) Models

PDX models entail a direct injection of tumor tissue of a patient into immunodeficient mice, which allows retaining cellular heterogeneity, histoarchitecture, and, to a certain degree, stroma of a tumor. In contrast to conventional xenografts established using immortalized cell lines, PDX models preserve the molecular typology of the donor tumor at each subsequent passage, including relevant driver mutations, gene expression signatures and drug responsiveness signatures *[Janitri Vet. Al., 2024]*.

Relevance to personalized nanomedicine

Mimicking inter patient heterogeneity: PDX models resemble the genetic and phenotypic variation among subtypes of breast cancer (HR+, HER2+ and TNBC) to provide a platform to interrogate nanocarriers targeting specific molecular changes.

1. Drug resistance modeling: PDX models of therapy-resistant tumors would offer an excellent way to test the development of nanomedicine formulations against resistance mechanisms.
2. Analysis of targeting: Nanocarriers can be functionalized with tumor-specific ligands or antibodies, or aptamers, and the potential of those nanoparticles to target the tumor and impact biodistribution and tumour penetration can be tested in an in vivo model mimicking human tumour biology.

The lack of functional human immune system constrains PDX models even despite their strengths and makes assessing nanomedicine as combined with immunotherapy challenging. An emergent solution entails humanized PDX models, which include human hematopoietic stem cells or immune cell subsets *[Guo L et. al., 2024]*.

5. Microfluidic Tumor-on-Chip and 3D Organoids

3D organoids

Organoids are self-organized, tumor-reduced in size structures produced by patient tumour cells or tissues grown underground matrices (e.g., Matrigel) designed to resemble the extracellular matrix (ECM). They are a perfectly faithful representation of the cellular composition and genetic changes as well as functional profile of the original

tumor, and thus provide an ex vivo model between the monolayer cultures and the in vivo systems *[Hwangbo Het. Al., 2024]*.

Nanomedicine application:

Nanocarrier permeation studies: Organoids allow testing the effects of nanoparticle characteristics (size, charge, surface modification) that affect the tissue penetration and distribution into a tumor-like structure.

Drug sensitivity profiling: Since they will have exposed the organoids to different nanotherapeutics, scientists can then determine the best formulation to use depending on an individual with the tumor. Co-culture systems: 3D incorporation of stromal and immune cells in organoid cultures will give an understanding on how nanomedicine influences the tumor-stroma or tumor-immune interactions *[Abdullah KM et. al., 2025]*.

Microfluidic tumor-in-chips systems

Tumor-on-chips are termed phenotypically similar microfluidic platforms that confine 3D cell cultures within micro-engineered channels, simulating most physical and biochemical characteristics of the tumor microenvironment, such as nutrient gradients, shear stress, and vascular-like flow.

Benefits of personalized **nanomedicine:**

1. Microfluidic systems can be used to perform dynamic testing of nanoparticle delivery, accumulation and clearance under flow conditions that closely mimic blood.
2. Vascular mimicry: Endothelial cell-lined channels were incorporated to enable a study of the extravasation of nanoparticles as well as the infiltration into the tumor environment in a controlled environment.
3. High-throughput possibility: Tumor-on-chip platforms can be miniaturized and multiplexed, so that a large number of nanocarriers can be screened with a relatively small number of assays.

Collectively, organoids combined with Tumor-on-chip structures create complimentary platforms to mecanistic and functional studies to deliver predictive data enabling determination of nanomedicine candidates likely to pass in vivo tests *[Wan L et. al., 2020]*.

AI-based Design and In Silico Modeling of Nanocarriers

Making nanocarriers optimal to target individual tumors in individual patients is a daunting task, as the many factors that determine efficacy and safety include size, shape, surface chemistry, ligand density, cargo type, release profile and many more. Artificial

intelligence (AI) and machine learning (ML) augment in silico modeling that provide the capabilities of expediting personalized nanomedicine rational design.

Design of nanomedicine

1. Molecular dynamics (MD) simulations: MD modeling contributes to the appearance of the structural stability, the drug loading capacity and the release profile of nanocarriers under simulated biological conditions.
2. Quantitative structure-activity relationship (QSAR) models: QSAR modeling: The physicochemical features of nanocarriers can be correlated with biological efficacy endpoints using QSAR tools to predict how a nanocarrier might perform in a specific entity.
3. Pharmacokinetic/pharmacodynamic (PK/PD) modeling: In silico PK/PD models can be used to predict nanoparticle distribution, metabolism and tumor accumulation in silico, bypassing the use of animal models [Bhange M *et. al.*,2025].

Nanomedicine and AI development AI in nanomedicine development

On learned large body of nanoparticle formulations and biological outcomes, AI algorithms can:

1. Predict best nanocarriers designs to isolate certain tumor type or molecular profile.
2. Find the trends between attributes of nanocarriers and efficacy/toxicity.
3. Control the adaptive design, allowing quickly iterating and enhancing prototypes of nanoparticles.

New AI apps also "combine multi-omics information (genomic, proteomic, transcriptomic) to suggest nanomedicine constructions to personalize against the molecular fingerprint of a tumor to a patient ushering in a new era of precision nanotherapy *[Das KPet. Al., 2023].*

6. Future Directions

The meeting between the PDX models, organoids, microfluidic systems, and the AI-based design is the essential solution to curbing the current bottlenecks in the development of the personalized nanomedicine. In the future, combined systems with multiple functionalities, including organoid-on-chips coupled with AI-aided nanocarrier optimization, are expected, with potentially much more predictive, time-saving, and economical preclinical study workflows. It will be imperative to overcome existing limitations such as scalability, standardization as well as regulatory validation in order to enjoy successful clinical translation *[Chauhdari T et. al., 2025].*

Next Generation Clinical Trials

The breast cancer therapeutics clinical trials landscape is changing large-scale due to the rise of new technology, patient-focused care model, and challenges associated with the new technology like nanomedicine. The traditional trial design tends to have rigid, time-consuming, and resource-intensive challenges that can hardly be confronted by nanotherapeutics case. Advances in personalized nanomedicine are approaching clinical practice and next-generation clinical trial designs are required to achieve efficient, ethical and scientifically sound assessments. This part is about the drawbacks of the traditional designs of trials and the discussion of innovative models such as adaptive designs, basket trials, umbrella trials, integrate AI designs, decentralized trials, and other designs that characterize the future path of clinical research in breast cancer nanomedicine [*Zardavas D et. Al., 2016].*

The Restrictions of Traditional Trial Designs as a System to Assess Nanotherapeutics

Clinical trials traditionally follow a straight-line, phase-oriented development process, with Phase I focusing on safety and dose determination, Phase II on rudimentary success, and Phase III on large-scale confirmation. Despite its effectiveness in offering numerous cancer treatments, this concept has some disadvantages when used to nanomedicine:

1. Complex pharmacokinetics and biodistribution: Traditional trial designs are not as attentive to the non-linear PK/PD relationship, organ-specific uptake, and irregular clearance mechanisms that are typically present in nanomedicines.
2. Inadequate stratification: Conventional trials usually employ a wide level of patient stratification (such as tumor stage) and neglect to take into consideration biological and molecular subtypes that are probably crucial to the response to nanotherapeutics.
3. Stiff procedures: Because conventional trials are rigid, they take a long time to incorporate new information that may come to light throughout the study process and may give patients the incorrect dose or combinations.
4. Expensive and time-consuming procedures: The standard trial approach is strained by the complexity of nanomedicine, which necessitates long-term monitoring to ensure safety and efficacy.

These limitations call for creative solutions that are data-driven, flexible, and capable of managing the complexities of customized nanomedicine.

Adaptive clinical trial: flexibility and real-time decision making

A paradigm change toward more adaptable, effective, and patient-centered trial design can be attributed to adaptive clinical trials. Prior rules in an adaptive trial permit trial

parameters to be changed following the analysis of interim results while maintaining statistical validity and scientific rigor.

Important characteristics of nanomedicine adaptive trial:

1. **Dynamic dose optimization:** The dose response curves may be very intricately relations with nanoparticle preparations; adaptive trials permit the real-time modulation of the level of dose in order to maximize therapeutic windows.
2. **Futility or success early stopping:** In case of inefficacy or excessive benefit at interim termination, it is possible to change or stop a trial, savings resources and serving patients.
3. **Enrichment methods:** Adaptive approaches permit patient sub-groups (e.g. particular molecular subtypes) to be identified and enriched upon who receive the most benefit of the nanotherapy.
4. **Refinement of combinatorial approaches:** It is frequent to use co-therapies in nanomedicine trials (e.g. immunotherapy); in adaptive designs, combinations can be explored to exploit synergy.

The adaptive characteristics of the adaptive designs match the realization that breast cancer is not only heterogeneous but also that nanocarriers behave in a complex way in the body *[Mahajan Ret. Al., 2010]*.

Nanomedicine of Breast Cancer: Basket Trials and Umbrella Trials

The use of the basket and umbrella trial design the innovations that were created in the area of precision oncology provide the potent platforms of the examination of the nanotherapeutics selective to the molecular alterations within the categories of the tumor, or in the case of breast cancer subtypes.

Basket trials

Basket trials also enroll patients that share a common molecular aberration (e.g., a PIK3CA mutation or HER2 overexpression), but not established etiology. This model would especially be applicable in the case of nanocarriers functionalized to target particular molecular markers or agents that target a specific pathway. Potential example use of a HER2-targeting nanoparticle containing a chemotherapeutic or siRNA may be trialed in patients with HER2- positive breast, gastric and ovarian cancers in one basket trial.

Efficiency: The rarity of molecular subtype per cancer is overcome by aggregating patients with rare molecular subtypes across cancers, and basket trials speed up accrual and lead to broader evidence on nanomedicine performance.

Umbrella trials

Umbrella trials concentrate on one type of tumor (e.g., breast cancer), and they assign patient to arms depending upon the molecular features or biomarkers. Both arms concentrate on another targeted therapy or nanomedicine specific to that molecular subgroup.

Example use: An umbrella trial of breast cancer may contain:

1. Knowledge on HR+ arm of hormone-conjugated nanocarriers.
2. HER2+ arm, which is going to be treated with HER2- directed nanoparticles.
3. TNBC arm working on nanocarriers as immuno-nanotherapy or gene editing.

The model can accommodate parallel testing of a multiplicity of nanomedicine strategies in a single, coherent trial infrastructure so that such precision can be introduced in the association of therapy with tumor biology.

Digital twins, machine learning, and artificial intelligence in trial design. The use of these technologies and techniques to trial design with the goal of ensuring robust development and testing of trial designs lies at the nexus of artificial intelligence, machine learning, and digital twin concepts. During nanomedicine studies, multidimensional data such as genomes, imaging, PK/PD, and patient-reported outcomes provide a staggering amount of data [Park JJH *et al.*, 2020].

The characteristics of AI-driven trial design entail:

Prediction modeling: The AI tools can be used to predict how patients will react, find the best nanocarriers design, and can advise them on the adaptive randomization methodologies.

1. Adaptive protocol change: ML algorithms can examine the real-time intermediate data flows to direct decisions to alter dose, add arms, or halt the study, in real-time.
2. Optimization of patient selection using AI: Multi-omics and radiomic data together allow hyper-immunoprecise nanomedicine testing of patients because AI allows the optimal stratification of trial participants *[Bhange M et. al.,2025].*

Digital twins - Decentralized Trial Part structures and Real-World Evidence

One of the new horizons of clinical trial innovation is the notion of digital twins, which are computational models of individual patients whose progress of diseases and response to treatment would be simulated. Use in nanomedicine clinical trials: Digital twin may be used to test nanoparticle-based formulation, dose and combination before administration in a patient in vivo. Ethical and efficiency advantages: The method would likely minimize the amount of unhelpful or harmful schemes that patients are

unknowingly subjected to and simplify the development of nanomedicine trials. The combination of the three technologies has the potential to make the next-generation nanomedicine trials more individual, responsive, and effective. Traditional trials usually take place on academic medical health facilities and their eligibility is highly specific so undermines generalizability. Decentralized clinical trials (DCTs) and real-world evidence (RWE) that provide a solution to such challenges are especially important in complex interventions such as nanomedicine. RWE is based on information that is measured beyond clinical trials, which include electronic health records, patient registries, and wearable devices. Including RWE to nanomedicine assessment can:

1. Widen representation: The data must be taken on diverse groups of people who hardly represent the general populace in traditional trials.
2. Determine safety over time: Watch out to see late toxicity or secondary effects that are specific to nanoparticle therapies.
3. Compare the effectiveness: Learn about the performance of nanomedicine in relation to the conventional treatment in everyday practice *[Mann DL et. al., 2024]*.

The decentralization trial scheme

Using telemedicine, local healthcare networks and digital tools, DCTs carry out trials through decentralized locations, not necessarily central sites of study.

1. Benefits to nanomedicine: Nanomedicine administration and monitoring is highly specific, thus DCTs will save patients on the elements that cause burden, increase accrual and retention by bringing the patient to the trial.
2. Digital health technology: Nanomedicine pharmacodynamics and patient-reported outcomes can be tracked in real time through wearable sensors, mobile apps and off-site imaging.

The next-generation trial design is an essential facilitator of precision nanomedicine in breast cancer. Through implementation of adaptive strategies, molecularly-based frameworks, AI-based optimization, and patient-centric strategies, the field can eliminate long-standing bottlenecks and provide safe, effective, and tumor-biology-specific nanotherapeutics. The utilization of digital technologies and the real-world data also makes sure that the evidence that is created is not only scientifically grounded but can also be applied to the range of patients with breast cancer existing today. These include regulatory considerations, manufacturing considerations and their ethical concerns as the this extraordinarily novel field of personalized nanomedicine moves toward clinical translation in breast cancer is greatly ushered with numerous regulatory issues, manufacturing issues and the ethical issues, that must be addressed to help guarantee patient safety, public confidence, and fair access. Nanoscale therapeutics is quite complicated, and the nature of personalized medicine is highly specific, so new

standards that would go beyond the scope of conventional drug development and approval principles are required *[Stern AD et. al., 2024]*.

Regulatory Berefts that are Unique to Personalized Nanomedicine

The products of nanomedicine industries can be an exception to the common definitions of pharmaceuticals, biologics, or medical devices categories but rather a mixed-rule type. This complexity is further increased in the case of personalized nanomedicine where nanocarriers can be produced in such a way that they can be unique to a specific tumor profile in an individual patient.

Some of key regulatory issues are:

1. **Diversity in terms of lack of standardized definitions and criteria:** Regulatory agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are continuing to clarify guidelines according to nanomedicine which has caused inconsistencies as to classification, approval process, or post-market surveillance.
2. **Complex pharmacokinetics and toxicity profiles:** For each patient, nanocarrier customization may lead to differing biodistribution, clearance, and off-target effects. This variability complicates establishing universal safety and efficacy benchmarks.
3. **Adaptive manufacturing oversight:** Manufacturing regulations should incorporate mid-production adjustments where properties of the nanocarrier are changed based on pre-configuration data or patient-specific metrics *[Rodríguez-Gómez FD et. al., 2025]*.

To address the above issues, there is a growing emphasis from authorities for risk-based frameworks, flexible trial structures, and synergy with developers in preliminary product design phases. QC Issues, Personalization of Nanocarriers provided PMP details Scaling Up Production While These personal drugs that are tailored differ significantly from traditional medicines which possess fixed chemical compositions because they allow alterations in size. Buffered solutions: 35 mm range within capillary tubes Buffer solution phenomena occur when 35 mm intervals of space stay unoccupied by liquid amidst cylindrical containers previously filled with buffered solution.

Scalability: The manufacturing infrastructure should be equal to the demand chain of production in little amounts that offer customization and the cost-effectiveness demand and be able to meet the requirements of regulations. The frontier of production solutions can provide modular or microfluid-based production systems that will possibly address

the same problem, but their application in clinical manufacturing pipelines needs to be validated.

Data analysis issues: Performing a good QC requires highly sophisticated tools of characterization (e.g, nanoparticle tracking analysis, dynamic light scattering, AFM) whose standardization is still incomplete.

Ethical Concerns: Privacy of Data, Data Access Equity and Informed Consent

There are pertinent ethical implications when implementing the use of customized nanomedicine:

1. **Data privacy:** Personalized nanotherapy design requires massive genomic, proteomic, and clinical data Privacy in research Data Privacy: Personalized nanotherapy design will be driven by large compendiums of genomic, proteomic, and clinical data. Storing, processing and sharing of this sensitive information should be secured with priority, to ensure the confidentiality of patients is kept, and to keep the trust of the people.

2. **Fairness in access:** The accessibility to personalized nanomedicine can ultimately result in increased healthcare disparities because of the cost and technology demands. A method to achieve equal opportunity, such as policy, pricing approaches, and collaboration between the governments and the non-state entities, is essential to avoid the increase in disparity among the underprivileged and well-off groups.

3. **Informed consent:** Patients should receive detailed information about the nature of risks and uncertainties unique to nanomedicine such as the possibility of an off-target effect and long-term safety issues, as well as the fact that many types of nanotherapeutics are already experimental. Adequate consents involving simple, easy to understand procedures that cater varying patient groups are mandatory.

4. Personalized Nanomedicine will revolutionize the treatment of breast cancer, yet it will depend on the resolution of the regulatory, manufacturing, and ethical issues through multidisciplinary efforts *[Brothers KB et. al., 2015].*

Designing Precision Oncology with the use of Nanomedicine

As the field of breast cancer treatment enters a new era of precision oncology, nanomedicine is emerging as the newest significant invention that could transform patient monitoring, therapeutic delivery, and diagnostics. A future where not just highly effective therapies but also tailored, adaptive, and accessible therapeutics will be possible thanks to the convergence of nanotechnology, digital health, immunotherapy, and systems biology. The present section sheds light on the developing patterns that will

influence nanomedicine's future in the field of breast cancer. Integration of wearable technology, biosensors, and nanomedicine: The use of nanotechnology in biosensors and wearable technologies is revolutionizing the way that breast cancer, treatment results, and patient health are tracked in real time. Nanomaterials Nanofabrics can improve the sensitivity and specificity of a biosensor that targets exosomes, circulating tumor DNA, or other indicators such as HER2 and estrogen receptors [Sabit Het. Al., 2015]. The concentration of nanocarriers in the bloodstream (such as temperature, pH, and glucose level) or continuous noninvasive monitoring may be possible with wearables equipped with nanobiosensors. In addition to enhancing quality of life and patient comfort, the latter allow for proactive intervention, early relapse warning, and personalized therapy changes.

Synergistic Strategies- Combinations of Nanomedicine with Targeted Biologics and Immunotherapy The combination between nanomedicine and other cutting-edge techniques, like immunotherapy and tailored biologics, will be increasingly utilized in future treatments. Chemotherapeutic drugs and immune modulators can be delivered via nanocarriers, which enhance tumor immunogenicity and disrupt immunological silence in the tumor microenvironment. As an illustration, along with a cytotoxic agent, checkpoint inhibitors, cytokines, or tumor antigen can be encapsulated into nanoparticles because, after delivery, they will be used with the utmost specificity to tumors, reducing systemic toxicity. In a like manner, the efficacy of HER2 or EGFR specific biologics can be improved by nanocarriers that have ligand functionalization to promote tumor accumulation as well as prolonged release. The combination approaches are promising and can target resistant or aggressive subtypes of breast cancer such as a triple-negative one *[Zhang RX et. al., 2016].*

Collaboration, Consortia and Open Innovation as Future of Translational Frameworks

Multi-stakeholder partnership is necessary in the successful translation of the personalized nanomedicine to the industry, academia, regulatory bodies and patient organizations. Nanomedicine-specific international consortia are able to standardize, speed up the design of clinical trials, and facilitate the exchange of information. Open innovation models such as shared nanomaterial libraries, AI-aided design platform, and real-world data registries can help democratize technological improvement through increased rates of progress. The issues of manufacturing, approval of the given nanotherapeutics, and fair access to it can only be addressed through collaborative frameworks *[De Maria Marchiano R et. al., 2021].*

Popularity of Precision Oncology by Nanotechnology Vision

In the future, nanomedicine will become a key pillar of precision oncology, where not only the treatment is N-tailed to the tumor but is also N-adapted to the changing disease. Big data analytics, digital twins, and smart drug delivery systems combined with nanotechnology will provide highly customized treatment pathways that improve outcomes while lowering costs and toxicity. Instantaneity, synergy, and a commitment to equity will define the delivery of breast cancer care in this future vision, ensuring that the potential of nanotechnology is realized everywhere and for every patient [Adir O *et al.,* 2020].

Conclusion

One of the most promising advances in breast cancer care is the integration of nanotechnology with personalized medicine. Customized nanocarriers designed to match a tumor's molecular profile, microenvironment, and immune status can greatly improve the precision, efficacy, and safety of therapies, addressing tumor heterogeneity-a key challenge in treatment. Unlike standard approaches, personalized nanomedicine enables tailored delivery systems for specific subtypes such as hormone receptor-positive, HER2-positive, or triple-negative breast cancers, marking a major step toward precision oncology. Next-generation clinical trial designs, including adaptive, basket, and umbrella trials, along with real-time biomarkers and digital health tools, are accelerating the evaluation of nanomedicine. These approaches can streamline regulatory approvals and speed up patient access to effective therapies. Future research must deepen understanding of the tumor microenvironment, resistance mechanisms, and immunological factors to design smarter nanocarriers. At the same time, policies should establish clear regulatory frameworks, ensure robust post-market surveillance, and promote equitable access across socioeconomic and geographic divides. Successful clinical adoption of personalized nanomedicine will also require strong diagnostic infrastructure, real-time monitoring, and comprehensive training of healthcare professionals. Ultimately, precision nanomedicine and innovative trial designs signal a paradigm shift-bringing breast cancer treatment closer to being individualized, safer, and more effective for every patient.

Acknowledgement
The authors would like to express their sincere gratitude to *Deep Science Publisher* and the editorial team of this book for their invaluable support in the final publication process and for providing the opportunity to contribute to this esteemed volume.

Conflicts of Interest
The authors declare that there are no conflicts of interest related to this work.

Funding Source

No funding was received for the preparation of this book chapter.

Author Contribution

All authors have contributed equally to the conception, preparation, and completion of this book chapter.

References

Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. *The Breast, 66*, 15–23. *https://doi.org/10.1016/j.breast.2022.08.010*

Yersal, O., & Barutca, S. (2014). Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World Journal of Clinical Oncology, 5*(3), 412–424. *https://doi.org/10.5306/wjco.v5.i3.412*

Carlino, F., Solinas, C., Orditura, M., Bisceglia, M. D., Pellegrino, B., & Diana, A. (2024). Editorial: Heterogeneity in breast cancer: Clinical and therapeutic implications. *Frontiers in Oncology, 14*, 1321654. *https://doi.org/10.3389/fonc.2024.1321654*

Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez de la Lastra, J. M. (2022). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes & Diseases, 10*(4), 1367–1401. *https://doi.org/10.1016/j.gendis.2022.02.007*

Tachtsidis, A., McInnes, L. M., Jacobsen, N., Thompson, E. W., & Saunders, C. M. (2016). Minimal residual disease in breast cancer: An overview of circulating and disseminated tumour cells. *Clinical & Experimental Metastasis, 33*(6), 521–550. *https://doi.org/10.1007/s10585-016-9796-8*

Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., O'Neill, K. M., Balter, M. L., Fritz, Z. R., Androulakis, I. P., Schloss, R. S., & Yarmush, M. L. (2018). The growing role of precision and personalized medicine for cancer treatment. *Technology, 6*(3–4), 79–100. *https://doi.org/10.1142/S2339547818300020*

Mehta, R., Jain, R. K., & Badve, S. (2011). Personalized medicine: The road ahead. *Clinical Breast Cancer, 11*(1), 20–26. *https://doi.org/10.3816/CBC.2011.n.004*

Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022). The promise of nanotechnology in personalized medicine. *Journal of Personalized Medicine, 12*(5), 673. *https://doi.org/10.3390/jpm12050673*

Hristova-Panusheva, K., Xenodochidis, C., Georgieva, M., & Krasteva, N. (2024). Nanoparticle-mediated drug delivery systems for precision targeting in oncology. *Pharmaceuticals, 17*(6), 677. *https://doi.org/10.3390/ph17060677*

Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M. J., Amajd, A., Abo-Zaid, M. A., Castillo-Acobo, R. Y., Ismail, A. H., Amin, A. H., & Akhavan-Sigari, R. (2023). Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation. *Molecular Cancer, 22*(1), 169. *https://doi.org/10.1186/s12943-023-01865-0*

Sabit, H., Pawlik, T. M., Radwan, F., Abdel-Hakeem, M., Abdel-Ghany, S., Wadan, A. S., Elzawahri, M., El-Hashash, A., & Arneth, B. (2025). Precision nanomedicine: Navigating the

tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Molecular Cancer, 24(1), 160. *https://doi.org/10.1186/s12943-025-02357-z*

Boone, C. E., Wang, L., Gautam, A., Newton, I. G., & Steinmetz, N. F. (2022). Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 14(1), e1739. *https://doi.org/10.1002/wnan.1739*

Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C. M., Mobley, W. C., Nolan, G. P., Rosen, S. T., Tan, P., Yen, Y., & Zarrinpar, A. (2020). Enabling technologies for personalized and precision medicine. Trends in Biotechnology, 38(5), 497–518. *https://doi.org/10.1016/j.tibtech.2019.12.021*

Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023). Breast cancer heterogeneity and its implication in personalized precision therapy. Experimental Hematology & Oncology, 12(1), 3. *https://doi.org/10.1186/s40164-022-00363-1*

Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., *et al*. (2022). Subtypes of breast cancer. In H. N. Mayrovitz (Ed.), Breast cancer (Chapter 3). Exon Publications.*https://www.ncbi.nlm.nih.gov/books/NBK583808/ https://doi.org/10.36255/exon-publications-breast-cancer-subtypes*

Mi, P. (2020). Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics, 10(10), 4557–4588. *https://doi.org/10.7150/thno.38069*

Lei, Z. N., Tian, Q., Teng, Q. X., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. S. (2023). Understanding and targeting resistance mechanisms in cancer. MedComm, 4(3), e265. *https://doi.org/10.1002/mco2.265*

Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., Nwadike, U. G., Ogbodo, J. O., Umeh, B. U., Ossai, E. C., & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6), e17488. *https://doi.org/10.1016/j.heliyon.2023.e17488*

Tarride, J. E., Cheung, M., Hanna, T. P., *et al*. (2022). Platform, basket, and umbrella trial designs: Issues around health technology assessment of novel therapeutics: Discussion paper. Canadian Agency for Drugs and Technologies in Health. *https://www.ncbi.nlm.nih.gov/books/NBK603602/*

Swierczewska, M., Liu, G., Lee, S., & Chen, X. (2012). High-sensitivity nanosensors for biomarker detection. Chemical Society Reviews, 41(7), 2641–2655. *https://doi.org/10.1039/c1cs15238f*

Liu, S. (2012). Epigenetics advancing personalized nanomedicine in cancer therapy. Advanced Drug Delivery Reviews, 64(13), 1532–1543. *https://doi.org/10.1016/j.addr.2012.08.004*

Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023). Nanoparticles as drug delivery systems: A review of the implication of nanoparticles' physicochemical properties on responses in biological systems. Polymers, 15(7), 1596. *https://doi.org/10.3390/polym15071596*

Sorrentino, C., Ciummo, S. L., Fieni, C., & Di Carlo, E. (2024). Nanomedicine for cancer patient-centered care. MedComm, 5(11), e767. *https://doi.org/10.1002/mco2.767*

Molla, G., & Bitew, M. (2024). Revolutionizing personalized medicine: Synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines, 12(12), 2750. *https://doi.org/10.3390/biomedicines12122750*

Li, Y., Kong, X., Wang, Z., & Xuan, L. (2022). Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment. Journal of Cellular and Molecular Medicine, 26(5), 1351–1362. *https://doi.org/10.1111/jcmm.17124*

Zhou, Z., Zhang, R., Zhou, A., Lv, J., Chen, S., Zou, H., Zhang, G., Lin, T., Wang, Z., Zhang, Y., Weng, S., Han, X., & Liu, Z. (2024). Proteomics appending a complementary dimension

to precision oncotherapy. Computational and Structural Biotechnology Journal, 23, 1725–1739. *https://doi.org/10.1016/j.csbj.2024.04.044*

Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes: Structure, composition, types, and clinical applications. Heliyon, 8(5), e09394. *https://doi.org/10.1016/j.heliyon.2022.e09394*

Choudhary, S., Gupta, L., Rani, S., Dave, K., & Gupta, U. (2017). Impact of dendrimers on solubility of hydrophobic drug molecules. Frontiers in Pharmacology, 8, 261. *https://doi.org/10.3389/fphar.2017.00261*

Alsaab, H. O., Alharbi, F. D., Alhibs, A. S., Alanazi, N. B., Alshehri, B. Y., Saleh, M. A., Alshehri, F. S., Algarni, M. A., Almugaiteeb, T., Uddin, M. N., & Alzhrani, R. M. (2022). PLGA-based nanomedicine: History of advancement and development in clinical applications of multiple diseases. Pharmaceutics, 14(12), 2728. *https://doi.org/10.3390/pharmaceutics14122728*

Baranwal, J., Barse, B., Di Petrillo, A., Gatto, G., Pilia, L., & Kumar, A. (2023). Nanoparticles in cancer diagnosis and treatment. Materials, 16(15), 5354. *https://doi.org/10.3390/ma16155354*

Sen, S., Xavier, J., Kumar, N., Ahmad, M. Z., & Ranjan, O. P. (2023). Exosomes as natural nanocarrier-based drug delivery system: Recent insights and future perspectives. 3 Biotech, 13(3), 101. *https://doi.org/10.1007/s13205-023-03521-2*

Feng, Y., Tang, Q., Wang, B., Yang, Q., Zhang, Y., Lei, L., & Li, S. (2024). Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. Journal of Nanobiotechnology, 22(1), 737. *https://doi.org/10.1186/s12951-024-03005-2*

Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020). Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review. Journal of Controlled Release, 319, 135–156. *https://doi.org/10.1016/j.jconrel.2019.12.041*

Vasudev, V. A., Mutthuraj, D., Aruna, G. L., & Basalingappa, K. M. (2024). A critical review on: Comprehending breast cancer in men with reference to female. *National Journal of Pharmaceutical Sciences*, *4*(1), 27–39. *https://doi.org/10.22271/27889262.2024.v4.i1a.93*

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies: An updated review. Cancers, 13(17), 4287. *https://doi.org/10.3390/cancers13174287*

Pal, R., Pandey, P., Chawra, H. S., & Khan, Z. (2025). Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment. *Pharmaceutical Nanotechnology*.

Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023). Emerging targeted therapies for HER2-positive breast cancer. Cancers, 15(7), 1987. *https://doi.org/10.3390/cancers15071987*

Pradhan, R., Dey, A., Taliyan, R., Puri, A., Kharavtekar, S., & Dubey, S. K. (2023). Recent advances in targeted nanocarriers for the management of triple negative breast cancer. Pharmaceutics, 15(1), 246. *https://doi.org/10.3390/pharmaceutics15010246*

Shi, Y., & Lammers, T. (2019). Combining nanomedicine and immunotherapy. Accounts of Chemical Research, 52(6), 1543–1554. *https://doi.org/10.1021/acs.accounts.9b00148*

Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018). Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics. AAPS Journal, 20(6), 108. *https://doi.org/10.1208/s12248-018-0267-9*

Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020). Combination therapy and nanoparticulate systems: Smart approaches for the effective treatment of breast cancer. Pharmaceutics, 12(6), 524. *https://doi.org/10.3390/pharmaceutics12060524*

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. *https://doi.org/10.1038/nrc.2016.108*

Wu, D., Si, M., Xue, H. Y., & Wong, H. L. (2017). Nanomedicine applications in the treatment of breast cancer: Current state of the art. International Journal of Nanomedicine, 12, 5879–5892. *https://doi.org/10.2147/IJN.S123437*

Boix-Montesinos, P., Soriano-Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021). The past, present, and future of breast cancer models for nanomedicine development. Advanced Drug Delivery Reviews, 173, 306–330. *https://doi.org/10.1016/j.addr.2021.03.018*

Janitri, V., ArulJothi, K. N., Ravi Mythili, V. M., Singh, S. K., Prasher, P., Gupta, G., Dua, K., Hanumanthappa, R., Karthikeyan, K., & Anand, K. (2024). The roles of patient-derived xenograft models and artificial intelligence toward precision medicine. MedComm, 5(10), e745. *https://doi.org/10.1002/mco2.745*

Hwangbo, H., Chae, S., Kim, W., Jo, S., & Kim, G. H. (2024). Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues. Theranostics, 14(1), 33–55. *https://doi.org/10.7150/thno.90093*

Abdullah, K. M., Sharma, G., Singh, A. P., & Siddiqui, J. A. (2025). Nanomedicine in cancer therapeutics: Current perspectives from bench to bedside. Molecular Cancer, 24(1), 169. *https://doi.org/10.1186/s12943-025-02368-w*

Wan, L., Neumann, C. A., & LeDuc, P. R. (2020). Tumor-on-a-chip for integrating a 3D tumor microenvironment: Chemical and mechanical factors. Lab on a Chip, 20(5), 873–888. *https://doi.org/10.1039/c9lc00550a*

Bhange, M., & Telange, D. (2025). Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: A comprehensive review. Discover Oncology, 16(1), 77. *https://doi.org/10.1007/s12672-025-01821-y*

Das, K. P., & J, C. (2023). Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. Frontiers in Medical Technology, 4, 1067144. *https://doi.org/10.3389/fmedt.2022.1067144*

Chauhdari, T., Zaidi, S. A., Su, J., & Ding, Y. (2025). Organoids meet microfluidics: Recent advancements, challenges, and future of organoids-on-chip. In Vitro Models, 4(1), 71–88. *https://doi.org/10.1007/s44164-025-00086-7*

Zardavas, D., & Piccart-Gebhart, M. (2016). New generation of breast cancer clinical trials implementing molecular profiling. Cancer Biology & Medicine, 13(2), 226–235. *https://doi.org/10.20892/j.issn.2095-3941.2015.0099*

Mahajan, R., & Gupta, K. (2010). Adaptive design clinical trials: Methodology, challenges and prospect. Indian Journal of Pharmacology, 42(4), 201–207. *https://doi.org/10.4103/0253-7613.68417*

Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K., & Mills, E. J. (2020). An overview of precision oncology basket and umbrella trials for clinicians. CA: A Cancer Journal for Clinicians, 70(2), 125–137. *https://doi.org/10.3322/caac.21600*

Mann, D. L. (2024). The use of digital healthcare twins in early-phase clinical trials: Opportunities, challenges, and applications. JACC: Basic to Translational Science, 9(9), 1159–1161. *https://doi.org/10.1016/j.jacbts.2024.08.002*

Stern, A. D., & Trusheim, M. (2024). Transformation of the clinical trial enterprise: Lessons learned from the COVID-19 pandemic: Final report (Decentralized clinical trials and digital health technologies). Office of the Assistant Secretary for Planning and Evaluation (ASPE). *https://www.ncbi.nlm.nih.gov/books/NBK609002/*

Rodríguez-Gómez, F. D., Monferrer, D., Penon, O., & Rivera-Gil, P. (2025). Regulatory pathways and guidelines for nanotechnology-enabled health products: A comparative review of EU and US frameworks. Frontiers in Medicine, 12, 1544393. *https://doi.org/10.3389/fmed.2025.1544393*

Brothers, K. B., & Rothstein, M. A. (2015). Ethical, legal and social implications of incorporating personalized medicine into healthcare. Personalized Medicine, 12(1), 43–51. *https://doi.org/10.2217/pme.14.65*

Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016). Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives. Journal of Controlled Release, 240, 489–503. *https://doi.org/10.1016/j.jconrel.2016.06.012*

De Maria Marchiano, R., Di Sante, G., Piro, G., Carbone, C., Tortora, G., Boldrini, L., Pietragalla, A., Daniele, G., Tredicine, M., Cesario, A., Valentini, V., Gallo, D., Babini, G., D'Oria, M., & Scambia, G. (2021). Translational research in the era of precision medicine: Where we are and where we will go. Journal of Personalized Medicine, 11(3), 216. *https://doi.org/10.3390/jpm11030216*

Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky-Roitman, J., Lammers, T., & Schroeder, A. (2020). Integrating artificial intelligence and nanotechnology for precision cancer medicine. Advanced Materials, 32(13), e1901989. *https://doi.org/10.1002/adma.201901989*

Tang, X., Loc, W. S., Dong, C., Matters, G. L., Butler, P. J., Kester, M., Meyers, C., Jiang, Y., & Adair, J. H. (2017). The use of nanoparticulates to treat breast cancer. Nanomedicine, 12(19), 2367–2388. *https://doi.org/10.2217/nnm-2017-0202*

Mittmann, N., Chan, K. K. W., Cheung, M., *et al*. (2022). Platform, basket, and umbrella trial designs: Stakeholder perspectives of novel therapeutics: Discussion paper. Canadian Agency for Drugs and Technologies in Health. *https://www.ncbi.nlm.nih.gov/books/NBK603603/*